Key result
Commercially available FCV vaccine immune sera failed to neutralize 22.2% to 69.4% of 36 FCV field isolates, indicating significant differences in neutralizing antigenicity.
Commercially available FCV vaccines show significant gaps in neutralizing antigenicity against field isolates prevalent in Japan, highlighting the need for vaccine improvement.
Current FCV vaccines may leave many field isolates unneutralized in cats; hypothesis-generating for updated vaccine strains.
Four types of commercially available feline calicivirus (FCV) vaccine were compared in terms of their efficacy on the basis of the ability of the sera of specific-pathogen-free cats immunized by two injections of each type of vaccine to neutralize FCV field isolates. Each vaccine immune serum neutralized relatively well strains F4, F9, and 255, which were FCV laboratory strains. As to 36 strains of field isolates, however, vaccines A, B, C, and D immune sera did not neutralize 18-20 of the strains (50.0%-55.6%), 19-22 of the strains (52.8%-61.1%), 22-25 of the strains (61.1%-69.4%), and 8-16 of the strains (22.2%-44.4%), respectively. These results indicate that there is much difference in neutralizing antigenicity between the existing vaccine strains and the FCV strains that are prevalent in Japan, suggesting the need for improvement of FCV vaccines.
No takes yet. Share an insight, caveat, or question.
Hohdatsu et al. (1999) studied Feline calicivirus (FCV) (n=8). Commercially available feline calicivirus (FCV) vaccines was evaluated on Ability of vaccine immune sera to neutralize FCV field isolates. Commercially available FCV vaccine immune sera failed to neutralize 22.2% to 69.4% of 36 FCV field isolates, indicating significant differences in neutralizing antigenicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: